Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC).
Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.
Company Details
- Employees
- 18
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.flamingotx.com
Flamingo Therapeutics Questions
Flamingo Therapeutics's website is http://www.flamingotx.com
Flamingo Therapeutics's LinkedIn profile is https://www.linkedin.com/company/flamingo-therapeutics
Flamingo Therapeutics has
18 employees.
View email and phone details for 18
employees at Flamingo Therapeutics.
Flamingo Therapeutics's industry is
Biotechnology Research
Flamingo Therapeutics's top competitors are
Confo Therapeutics,
Augustine Therapeutics,
Exevir,
Agomab,
Etherna,
Montis Biosciences,
Remynd,
Ablynx,
Mrm Health,
Rewind Therapeutics.
Flamingo Therapeutics's categories are Biotechnology Research
